Efficacy of peripheral blood stem cell transplantation versus conventional chemotherapy on anaplastic large-cell lymphoma:a retrospective study of 64 patients from a single center

作     者：Xiao-Hui He Bo Li Shuang-Mei Zou Mei Dong Sheng-Yu Zhou Jian-Liang Yang Li-Yan Xue Sheng Yang Peng Liu Yan Qin Chang-Gong Zhang Xiao-Hong Han Yuan-Kai Shi 

作者机构：Department of Medical Oncology Deparkment of PathologyCancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China. 

出 版 物：《Chinese Journal of Cancer》 (Chin. J. Cancer)

年 卷 期：2012年第31卷第11期

页      面：532-540页

核心收录：

学科分类：090603[农学-临床兽医学] 0710[理学-生物学] 07[理学] 071009[理学-细胞生物学] 09[农学] 0906[农学-兽医学] 0901[农学-作物学] 090102[农学-作物遗传育种] 

主　　题：造血干细胞移植 疗效比较 淋巴瘤 外周血 化疗 变性 EFS 单因素分析 

摘      要：Anaplastic large-cell lymphoma(ALCL) is characterized by frequently presenting adverse factors at *** groups believed aggressive treatment strategies such as autologous stem cell transplantation brought survival benefit for ALCL ***,few compared these approaches with conventional chemotherapy to validate their ***,we report a study comparing the efficacy of peripheral blood stem cell transplantation(PBSCT) and conventional chemotherapy on ALCL.A total of 64 patients with primary systemic ALCL were studied *** median follow-up period was 51 months(range,1-167 months).For 48 patients undergoing conventional chemotherapy only,the 4-year event-free survival(EFS) and overall survival(OS) rates were 70.7% and 88.3%,***,16 patients underwent PBSCT,including 11 at first remission(CR1/PR1),3 at second remission,and 2 with disease progression during first-line *** 4-year EFS and OS rates for patients underwent PBSCT at first remission were 81.8% and 90.9%,*** with conventional chemotherapy,PBSCT did not show superiority either in EFS(P = 0.240) or in OS(P = 0.580) when applied at first *** analysis showed that patients with B symptoms(P = 0.001),stage III/IV disease(P = 0.008),bulky disease(P = 0.075),negative anaplastic lymphoma kinase(ALK) expression(P = 0.059),and age ≤ 60 years(P = 0.054) had lower ***,PBSCT significantly improved EFS in patients with B symptoms(100% vs.50.8%,P = 0.027) or bulky disease(100% vs.52.8%,P = 0.045) when applied as an up-front *** on these results,we conclude that,for patients with specific adverse factors such as B symptoms and bulky disease,PBSCT was superior to conventional chemotherapy in terms of EFS.